The Journal of Immunology, Vol 154, Issue 2 772-779, Copyright © 1995 by American Association of Immunologists

ARTICLES

Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15

T Takahashi, PB Chapman, SY Yang, I Hara, S Vijayasaradhi and AN Houghton
Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Reactivity of CD8+ T lymphocytes against human melanoma has been extensively characterized, but little is known about melanoma Ags recognized by CD4+ lymphocytes. We have identified CD4+ CTL that recognize shared melanoma Ag(s) expressed by autologous melanoma cells and a subset of allogeneic melanomas. The same Ag(s) was shared by autologous and positive allogeneic melanomas by cross-blocking experiments. Cytotoxicity was directed against epitopes presented by HLA-DR on target melanoma cells, and allelic typing revealed that cytotoxicity was restricted through HLA-DR15. These CD4+ T cells released IFN-gamma, IL-4, and TNF-alpha, but not IL-2, in response to HLA-DR15+ target cells. CD4+ T cells did not lyse DR15+ nonmelanoma cell types, including melanocytes or fibroblasts (induced to express HLA-DR by IFN-gamma). Thus, by cytotoxicity assays, shared Ags were only recognized on melanoma cells but not on normal melanocytes. In summary, this analysis shows that melanoma cells share an Ag that is presented by HLA-DR15.

This article has been cited by other articles:

				R. K. Swoboda, R. Somasundaram, L. Caputo, E. M. Ochoa, P. A. Gimotty, F. M. Marincola, P. Van Belle, S. Barth, D. Elder, D. Guerry, et al. Shared MHC Class II-Dependent Melanoma Ribosomal Protein L8 Identified by Phage Display Cancer Res., April 15, 2007; 67(8): 3555 - 3559. [Abstract] [Full Text] [PDF]

				M R Hussein, D A H Elsers, S A Fadel, and A-E M Omar Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J. Clin. Pathol., March 1, 2006; 59(3): 316 - 324. [Abstract] [Full Text] [PDF]

				E. S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy J. Immunol., January 15, 2004; 172(2): 1304 - 1310. [Abstract] [Full Text] [PDF]

				G. Consogno, S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B. M. Conti-Fine, C. Rugarli, C. Traversari, and M. P. Protti Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 Blood, February 1, 2003; 101(3): 1038 - 1044. [Abstract] [Full Text] [PDF]

				P. F. Robbins, M. El-Gamil, Y. F. Li, G. Zeng, M. Dudley, and S. A. Rosenberg Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma J. Immunol., November 15, 2002; 169(10): 6036 - 6047. [Abstract] [Full Text] [PDF]

				H. Y. Wang, J. Zhou, K. Zhu, A. I. Riker, F. M. Marincola, and R.-F. Wang Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells: Its Role in Extracellular Matrix Formation and Tumor Metastasis J. Exp. Med., June 3, 2002; 195(11): 1397 - 1406. [Abstract] [Full Text] [PDF]

				S. Hanabuchi, T. Ohashi, Y. Koya, H. Kato, A. Hasegawa, F. Takemura, T. Masuda, and M. Kannagi Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity J Natl Cancer Inst, December 5, 2001; 93(23): 1775 - 1783. [Abstract] [Full Text] [PDF]

				E. S. Schultz, B. Lethé, C. L. Cambiaso, J. Van Snick, P. Chaux, J. Corthals, C. Heirman, K. Thielemans, T. Boon, and P. van der Bruggen A MAGE-A3 Peptide Presented by HLA-DP4 Is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes Cancer Res., November 1, 2000; 60(22): 6272 - 6275. [Abstract] [Full Text]

				C. N. Baxevanis, I. F. Voutsas, O. E. Tsitsilonis, A. D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor J. Immunol., April 1, 2000; 164(7): 3902 - 3912. [Abstract] [Full Text] [PDF]

				H. M. Zarour, J. M. Kirkwood, L. S. Kierstead, W. Herr, V. Brusic, C. L. Slingluff Jr., J. Sidney, A. Sette, and W. J. Storkus Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells PNAS, January 4, 2000; 97(1): 400 - 405. [Abstract] [Full Text] [PDF]

				D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Cerottini, and P. Romero An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer Cancer Res., May 1, 1999; 59(9): 2167 - 2173. [Abstract] [Full Text] [PDF]

				S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 J. Exp. Med., March 1, 1999; 189(5): 871 - 876. [Abstract] [Full Text] [PDF]

				M. Yasukawa, H. Ohminami, S. Kaneko, Y. Yakushijin, Y. Nishimura, K. Inokuchi, T. Miyakuni, S. Nakao, K. Kishi, I. Kubonishi, et al. CD4+ Cytotoxic T-Cell Clones Specific for bcr-abl b3a2 Fusion Peptide Augment Colony Formation by Chronic Myelogenous Leukemia Cells in a b3a2-Specific and HLA-DR-Restricted Manner Blood, November 1, 1998; 92(9): 3355 - 3361. [Abstract] [Full Text] [PDF]

				S. Nakao, A. Takami, H. Takamatsu, W. Zeng, N. Sugimori, H. Yamazaki, Y. Miura, M. Ueda, S. Shiobara, T. Yoshioka, et al. Isolation of a T-Cell Clone Showing HLA-DRB1*0405-Restricted Cytotoxicity for Hematopoietic Cells in a Patient With Aplastic Anemia Blood, May 15, 1997; 89(10): 3691 - 3699. [Abstract] [Full Text] [PDF]